Metabotropic glutamate receptors and the control of chronic pain

Santina Chiechio, Ferdinando Nicoletti

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume12
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Metabotropic Glutamate Receptors
Chronic Pain
Pain
Ligands
Central Nervous System Diseases
Neuralgia
Therapeutic Uses
Epigenomics
Neurodegenerative Diseases
Schizophrenia
Anxiety
Pharmacology
Depression

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Metabotropic glutamate receptors and the control of chronic pain. / Chiechio, Santina; Nicoletti, Ferdinando.

In: Current Opinion in Pharmacology, Vol. 12, No. 1, 02.2012, p. 28-34.

Research output: Contribution to journalArticle

@article{d618ab73b9b2430eb5274c2ce3a09ef5,
title = "Metabotropic glutamate receptors and the control of chronic pain",
abstract = "Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.",
author = "Santina Chiechio and Ferdinando Nicoletti",
year = "2012",
month = "2",
doi = "10.1016/j.coph.2011.10.010",
language = "English",
volume = "12",
pages = "28--34",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Metabotropic glutamate receptors and the control of chronic pain

AU - Chiechio, Santina

AU - Nicoletti, Ferdinando

PY - 2012/2

Y1 - 2012/2

N2 - Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.

AB - Over the past two decades metabotropic glutamate (mGlu) receptor ligands have been investigated for their potential therapeutic effects in different disorders of the central nervous system (CNS), including anxiety, depression, schizophrenia, and neurodegenerative diseases. In addition, it has been widely demonstrated that mGlu receptors are able to modulate pain transmission both in inflammatory and neuropathic pain models. A large number of preclinical studies combining the use of selective ligands with the knockout strategy have revealed more details about the role of the different mGlu receptor subtypes in the modulation of pain information. This review will address the role of mGlu receptors in pain sensitivity focusing on different strategies to achieve pain control by targeting specific mGlu receptor subtypes. Specifically, pharmacological interventions aimed at inhibiting group I mGlu receptor-mediated signaling and/or potentiating groups II and III mGlu receptor signaling together with an epigenetic approach leading to an increased expression of mGlu2 receptors will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=84857238962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857238962&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2011.10.010

DO - 10.1016/j.coph.2011.10.010

M3 - Article

VL - 12

SP - 28

EP - 34

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 1

ER -